Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR -mutant non-small cell lung cancer and emergent MET amplification
作者: Viola W ZhuAlexa B SchrockSiraj M AliSai-Hong Ignatius Ou
作者单位: 1University of California, Irvine School of Medicine
2Foundation Medicine, Inc.
刊名: Lung Cancer: Targets and Therapy, 2019, Vol.2019 (default), pp.21-26
来源数据库: Dove Journal
DOI: 10.2147/LCTT.S190403
原始语种摘要: Exploring resistance mechanisms in patients with EGFR-mutant non-small cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies. Here we report a case of emergent MET amplification detected in a tumor sample from a patient with squamous cell carcinoma of the lung harboring EGFR L858R mutation after disease progression on erlotinib. The patient subsequently had a sustained partial response to a combination of full-dose osimertinib and crizotinib with excellent tolerance but eventually had central nervous system (CNS) progression. Comprehensive genomic profiling performed on the resected brain sample continued to demonstrate MET amplification as an acquired...
全文获取路径: Dove 
分享到:

×
关键词翻译
关键词翻译
  • combination 聚形
  • emergent 紧急的
  • amplification 放大
  • mutant 突变体
  • response 响应
  • cancer 癌症
  • squamous 具鳞的
  • brain 
  • carcinoma 癌症
  • developing 显影